General Information of the Disease (ID: M6ADIS0017)
Name
Hepatic fibrosis/cirrhosis
ICD
ICD-11: DB93
Full List of Target Gene(s) of This m6A-centered Disease Response
Protein patched homolog 1 (PTCH1)
In total 2 item(s) under this target gene
Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene [2]
Response Summary AcSDKP in liver fibrosis via m6A modification and Hedgehog pathway, which helps us to shed light on the molecular mechanism in liver fibrosis progression. WTAP targeted the 3'-UTR of Protein patched homolog 1 (PTCH1) mRNA, and administration of AcSDKP reduced the stability of Ptch1 mRNA.
Responsed Disease Hepatic fibrosis [ICD-11: DB93.0]
Responsed Drug AcSDKP Phase 2
Target Regulator Wilms tumor 1-associating protein (WTAP) WRITER
Target Regulation Down regulation
Pathway Response Hedgehog signaling pathway hsa04340
Cell Process Cell apoptosis
In-vitro Model HSC (Hematopoietic stem cell)
In-vivo Model Male Sprague-Dawley rats (375-400 g) liver fibrosis was induced by subcutaneous injection of carbon tetrachloride (CCl4) and olive oil (a ratio of 2:3) twice per week.
Experiment 2 Reporting the m6A-centered Disease Response by This Target Gene [3]
Response Summary ALKBH5 mediated Protein patched homolog 1 (PTCH1) activation via a m6A-dependent manner,ALKBH5 ameliorated liver fibrosis and suppressed HSCs activation via triggering PTCH1 activation in a m6A dependent manner.
Responsed Disease Hepatic fibrosis [ICD-11: DB93.0]
Target Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
Target Regulation Up regulation
Pathway Response Hedgehog signaling pathway hsa04340
In-vitro Model HSCs (Hepatic stellate cells(HSCs) were purchased from American Type Culture Collections (Manassas, VA))
In-vivo Model Liver fibrosis mice model was induced by intraperitoneal CCl4 injection for 12 weeks. The dose regimen for CCl4 in mice is 1 ml kg-1, diluted to 50% with olive oil twice per week for 12 weeks. Until 11 weeks, mice with liver-specific disruption of ALKBH5 were given hydrodynamic tail-vein injections of LV5-ALKBH5.
Full List of Crosstalk(s) between m6A Modification and Epigenetic Regulation Related to This Disease
In total 8 item(s) under this disease
Crosstalk ID: M6ACROT02001
m6A Regulator YTH domain-containing family protein 1 (YTHDF1)
m6A Target Collagen alpha-1 (COL1A1)
Epigenetic Regulator Cysteine methyltransferase DNMT3A (DNMT3A)
Regulated Target Suppressor of cytokine signaling 3 (SOCS3)
Crosstalk relationship DNA modification → m6A
Crosstalk ID: M6ACROT02002
m6A Regulator YTH domain-containing family protein 1 (YTHDF1)
m6A Target Collagen alpha-2(I) chain (COL1A2)
Epigenetic Regulator Cysteine methyltransferase DNMT3A (DNMT3A)
Regulated Target Suppressor of cytokine signaling 3 (SOCS3)
Crosstalk relationship DNA modification → m6A
Crosstalk ID: M6ACROT02003
m6A Regulator YTH domain-containing family protein 1 (YTHDF1)
m6A Target Collagen alpha-1 (III) chain (COL3A1)
Epigenetic Regulator Cysteine methyltransferase DNMT3A (DNMT3A)
Regulated Target Suppressor of cytokine signaling 3 (SOCS3)
Crosstalk relationship DNA modification → m6A
Crosstalk ID: M6ACROT02004
m6A Regulator YTH domain-containing family protein 1 (YTHDF1)
m6A Target Collagen alpha-2(V) chain (COL5A2)
Epigenetic Regulator Cysteine methyltransferase DNMT3A (DNMT3A)
Regulated Target Suppressor of cytokine signaling 3 (SOCS3)
Crosstalk relationship DNA modification → m6A
Crosstalk ID: M6ACROT02005
m6A Regulator YTH domain-containing family protein 1 (YTHDF1)
m6A Target Collagen alpha-2(VI) chain (COL6A2)
Epigenetic Regulator Cysteine methyltransferase DNMT3A (DNMT3A)
Regulated Target Suppressor of cytokine signaling 3 (SOCS3)
Crosstalk relationship DNA modification → m6A
Crosstalk ID: M6ACROT03079
m6A Regulator Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2)
m6A Target Fructose-bisphosphate aldolase A (ALDOA)
Regulated Target Histone H3 lysine 18 lactylation (H3K18la)
Crosstalk relationship m6A → Histone modification
Crosstalk ID: M6ACROT03159
m6A Regulator RNA demethylase ALKBH5 (ALKBH5)
m6A Target Zinc finger protein SNAI1 (SNAI1)
Epigenetic Regulator Lysine-specific demethylase 4C (KDM4C)
Regulated Target Histone H3 lysine 9 trimethylation (H3K9me3)
Crosstalk relationship Histone modification → m6A
Crosstalk ID: M6ACROT05650
m6A Regulator YTH domain-containing family protein 2 (YTHDF2)
m6A Target Circ_IRF2
Epigenetic Regulator Circ_IRF2
Regulated Target hsa-miR-29b-1-5p
Crosstalk relationship m6A → ncRNA
References
Ref 1 [Non-surgical treatment of osteoarthritis of large joints - new aspects]. Wien Med Wochenschr. 2009;159(3-4):76-86. doi: 10.1007/s10354-008-0603-2.
Ref 2 N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) mitigates the liver fibrosis via WTAP/m(6)A/Ptch1 axis through Hedgehog pathway. Gene. 2022 Mar 1;813:146125. doi: 10.1016/j.gene.2021.146125. Epub 2021 Dec 16.
Ref 3 ALKBH5 ameliorated liver fibrosis and suppressed HSCs activation via triggering PTCH1 activation in an m(6)A dependent manner. Eur J Pharmacol. 2022 May 5;922:174900. doi: 10.1016/j.ejphar.2022.174900. Epub 2022 Mar 19.
Ref 4 The Sirt1 Activators SRT2183 and SRT3025 Inhibit RANKL-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages and Down-Regulate Sirt3 in Sirt1 Null Cells. PLoS One. 2015 Jul 30;10(7):e0134391. doi: 10.1371/journal.pone.0134391. eCollection 2015.
Ref 5 Clinical pipeline report, company report or official report of GlaxoSmithKline.
Ref 6 Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014 Mar;13(3):217-36. doi: 10.1038/nrd4236.
Ref 7 Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer. 1999 Feb;35(2):208-13. doi: 10.1016/s0959-8049(98)00392-x.